抗肿瘤药物医保限制支付范围内肿瘤分期与临床分期对比分析
中图分类号 R979.1；F840.684 文献标志码 A 文章编号 1001-0408(2025)10-1166-06DOI 10.6039/j.issn.1001-0408.2025.10.03
Comparative analysis of tumor staging versus clinical staging in reimbursement scope restrictions under medical insurance for antineoplastic agents
ZHAO Dehua，LONG Xiaoqing，WANG Jisheng，FAN Hongying(Dept. of Medical Insurance and Pricing， Mianyang Third People’s Hospital/Sichuan Provincial Mental Health Center，Sichuan Mianyang ，China)
ABSTRACT OBJECTIVE To comparatively analyze tumor staging versus clinical staging in reimbursement scope restrictions under medical insurance for antineoplastic agents in order to better implement the medicare drug payment policy. METHODS Antineoplastic agents included in the National Basic Medical Insurance，Workers’ Compensation Insurance and Maternity Insurance Drug Catalogue(2024)(hereinafter referred to as the“Medical Insurance Catalog”)were used as research subject to compile and analyze reimbursement scope restrictions regarding tumor staging. By consulting clinical diagnosis and treatment guidelines and relevant literature ......
您现在查看是摘要页，全文长 19765 字符。